Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
274 hedge funds and large institutions have $2.8B invested in Apellis Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 93 increasing their positions, 92 reducing their positions, and 30 closing their positions.
384% more call options, than puts
Call options by funds: $102M | Put options by funds: $21.1M
100% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 30
11% more funds holding
Funds holding: 247 → 274 (+27)
1% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 92
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
6.89% less ownership
Funds ownership: 104.66% → 97.77% (-6.9%)
27% less capital inflows, than outflows
Capital inflows: $404M | Capital outflows: $554M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$39.3M |
| 2 |
Polar Capital Holdings
London,
United Kingdom
|
+$30.3M |
| 3 |
Millennium Management
New York
|
+$26.6M |
| 4 |
Deep Track Capital
Greenwich,
Connecticut
|
+$23.3M |
| 5 |
ING Group
Amsterdam,
Netherlands
|
+$20.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EcoR1 Capital
San Francisco,
California
|
-$197M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$53.8M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$34.7M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$30.4M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$28.5M |
APLS Hedge Fund Activity: Q3 2025 in Review
274 of the 7,661 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q3 2025, worth a combined $2.8B — up 23% from $2.28B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new APLS positions and 30 closed out — a net gain of 30 holders — while 93 added to existing stakes and 92 trimmed.
The largest buyer was Jennison Associates, adding an estimated $39.3M. The largest seller was EcoR1 Capital, cutting an estimated $197M.
- 274 institutional investors held Apellis Pharmaceuticals (APLS) as of Q3 2025, up from 247 in Q2 2025.
- Funds reported $2.8B of Apellis Pharmaceuticals stock for Q3 2025, up 23% quarter-over-quarter.
- 60 funds opened new Apellis Pharmaceuticals positions in Q3 2025 and 30 closed out, a net change of +30 holders.
- The largest Apellis Pharmaceuticals buyer in Q3 2025 was Jennison Associates, an estimated $39.3M added.
- The largest Apellis Pharmaceuticals seller in Q3 2025 was EcoR1 Capital, an estimated $197M sold.
Based on aggregated 13F filings for Q3 2025.